韩国批准销售新的干细胞的药物（法新社, 2012-01-20)

S. Korea approves sales of new stem cell drug

(AFP, 2012-01-20) 


Original: http://www.google.com/hostednews/afp/article/ALeqM5jrKtAH1a6ABJeK1s46AM4rPJOIFQ?docId=CNG.1c6dafea9831a4e285a8fd5725fe404e.81

首尔- 韩国政府药品监督管理局周四宣布批准世界上第一个的从其他人收集的医药使用干细胞作商业销售.

SEOUL — South Korea's government drug agency cleared the way Thursday for commercial sales of what it called the world's first approved medicine using stem cells collected from other people.

韩国食品和药物管理局称: 汉城Medipost开发的Cartistem将使用从新生儿脐带血干细胞辅助再生膝盖软骨.

Cartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns' umbilical cord blood, the Korea Food and Drug Administration said.

“Cartistem是世界上第一个批准的异体（从同一物种的不同个体采取）干细胞的药物，它可以提供新的治疗机遇给退化性关节炎患者”,政府在一份声明中表示.
"Cartistem is... the world's first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis," the administration said in a statement.

Medipost称私人投资者和政府基金已自2001年以来投资270亿韩元（$2380万美元）发展Cartistem. 此药物可以通过手术注射到患者的膝盖.
Medipost said 27 billion won ($23.8 million) from private investors and government funds had been invested to develop Cartistem since 2001. The drug can be injected into a patient's knees via surgery.

声明中称，自去年以来(药物)已经在美国进行临床试验.

Clinical trials have been under way in the United States since last year, the statement said.

Medipost发言人对法新社记者称, 两间世界排名前10位的制药公司正在谈判寻求全世界范围的药物许可使用权, 大规模的最终临床试验大可能会在2015年在美国开始.

Two of the world's top 10 drugmakers are in talks to seek a worldwide licence to make the drug, a Medipost spokesman told AFP, adding that final trials involving a large number of people would likely begin in the US in 2015.

免责声明: 以上中文翻译版本只供参考用途.
Disclaimer: The above Chinese translation version is for reference only.


Translated by Pat Chu on 2012-01-21